ArticleScientific reports2025
Dysregulation of adipocytokines via the hsa-miR-548ay-3p/PPARγ signaling pathway leads to cardiac fibrosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The context-dependent roles of PPAR-γ in adipocyte differentiation and obesity: a master regulator with dual functions.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cardiac fibrosis is a chief cause of atrial fibrillation (AF), yet its mechanism is not fully understood. Our previous study found that fibrosis-related adipocytokines were dysregulated in epicardial adipose tissue (EAT) from patients with AF. The present study explored the factors inducing adipocytokine dysregulation and the mechanism by which this dysregulation leads to cardiac fibrosis. The effects of inhibition of PPARγ-induced adipocytokine dysregulation on cardiac fibroblasts (CFs) were investigated by co-culturing with conditioned medium (CM). miRNA targeting PPARγ was screened by combining the TargetScan database, our previous miRNA sequencing data, and validation in EAT samples. The function of hsa-miR-548ay-3p was explored using in vitro and in vivo experiments. The mechanism underlying hsa-miR-548ay-3p/ PPARγ/adipocytokine dysregulation-induced CFs activation was explored by RNA sequencing and validated using in vitro experiments. PPARγ was decreased in EAT from patients with AF, and CM of EAT from patients with AF activated CFs. Inhibition of PPARγ resulted in adipocytokines dysregulation, which then induced the activation of CFs. hsa-miR-548ay-3p induced adipocytokines dysregulation by targeting PPARγ, with this dysregulation resulting in cardiac fibrosis via the TGF-β1/SMAD2/3 signaling pathway. In conclusion, we found that hsa-miR-548ay-3p/PPARγ-induced adipocytokine dysregulation activates CFs, resulting in cardiac fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.